Cardiovascular Drug-Eluting Stent Developers, Products, Status

Developers of Cardiovascular Drug-Eluting Stents

CompanyStent DrugStatus
Abbott Vascular DevicesZoMaxxZotarolimusIn clinicals; ZOMAXX II trial approved 6/05
Avantec Vascular (Goodman)DuraflexPimecrolimus In development
Biosensors InternationalBioMatrixBiolimus A9In trials; Expects CE Mark in 2006
Boston ScientificTaxus Express2PaclitaxelCE Mark 1/03; FDA approval 3/04
Boston ScientificTaxus LibertéPaclitaxelCE Mark 9/05 (launched 1/05); FDA approval expected mid-2006
Conor MedsystemsCoStarPaclitaxelCE Marked 2/06
Conor Medsystems(Next-generation CoStar) PimecrolimusPimecrolimus licensed from Novartis in 3/06; Testing two devices: one loaded with pimecrolimus and another with both pimecrolimus and paclitaxel
Cordis (J&J)CypherSirolimusCE Mark; FDA approved, U.S. launch 4/03
CordisCypher SelectSirolimusCE Mark in 2003
CordisCypher NeoSirolimus In development
CorNova(Undisclosed)(Undisclosed)In development
DevaxAxxess Plus (bifurcated)Biolimus A9In clinicals (positive first-in-man data reported 11/05)
DISA VascularStelliumPaclitaxelIn development
Estracure/Medivas/Picarus(Undisclosed)17-(beta)-EstradiolIn development
GuidantXience VEverolimusCE Mark 1/06; European launch pending
MedtronicEndeavorZotarolimusCE Mark 7/05; U.S. launch planned in 2007. RESOLUTE trial began 12/05
Occam International (subsidiary of Biosensors International)AxxionPaclitaxelCE Mark 7/05
Relisys Medical Devices(Undisclosed)PaclitaxelIn clinicals
Sahajanand Medical Technologies (SMT)InfinniumPaclitaxelCE Mark 12/05
Sorin Biomedica CardioJanus FlexTacrolimusCE Mark; launched in Europe 2/06
TerumoNoboriBiolimus A9Clinical trial launched 6/05
X-Cell MedicalEthos17-(beta)-EstradiolIn clinicals
XtentXtentBiolimus A9In clinicals; European launch planned in 2007, U.S. in 2009

Note: CV Therapeutics and MIV Therapeutics (among others) are developing coatings for coronary drug stents.Source: MedMarket Diligence, LLCRelated Tags: , ,

More Drug-Eluting Stents Nearing Market; Biotech Market Progress — April MedMarkets

In our April issue of MedMarkets, we cover the current and forecasted market for drug-eluting stents, considering the pending introductions of a number of competitors to established players J&J and Boston Scientific. We also look at the hard successes of biotech in bringing products to market and the growing success the industry is having in once again attracting invesment. Below is our outline of coverage:

  • Biomedtech, Combo Technologies Bolster Growth in Device Markets
  • Flurry of Cardiovascular Drug-Eluting Stents Nearing Market
  • MedMarket Outlook: Opportunities in Common Technology Threads
  • Early Stage Companies:
  •  
    • Intraoperative Determination of Tumor Margin
    • All -Polymer Hip Implant European Trial
    • Ultrasound-Assisted, Transdermal Insulin Delivery
  • Early Stage Company Financings: Active Implants, AngioScore, Aptus Endosystems, BlueBelt Technologies, CryoFluor Therapeutics, Ultradian Diagnostics
  • Recent Medtech Startups
  • Biotech Update: Carbon Nanotube Scaffolding Fosters Proliferation of Bone Cells
  • Drivers: California Judge OKs Stem Cell Research Agency
  • Leading Clinical Edge:
  •  
    • Measuring EPCs: A new Test for Heart Disease?
    • Artificial Nuscle Stronger Than Natural Muscle
    • “Neuro-chip” Leads to Improved Communication
    • U.K. Researchers to Produce Wound Monitor
    • Online (HTML) Only:
  •  
    •  
      •  
        • Articular Cartilage Paste Grafting Shows Promise
        • New Knee Repair Technique Introduced
        • Stent-Graft Improves Aneurysm Repair
        • Better Outcomes with Less-Invasive AAA Repair
        • CRT Devices Linked to Better Outcomes
        • Esophageal Stenting Found Effective
  • Developments
  •  
    • ISSYS Awarded Patent for Wireless Sensors
    • WorldHeart’s LVAS Enters Key Phase in Animal Testing
    • Sorin to Launch Cobalt Chrome Carbostent
    • ATS Announces First Implant of Annuloplasty Ring
    • Medtronic’s AAA Stent Receives FDA Approval
    • FDA OKs DexCom’s Glucose Monitoring System
    • FDA Clears Bone Graft Product
    • Regeneration Technologies Launches New Implant
    • Online (HTML) Only:
  •  
    •  
      •  
        • MicroCHIPS Develops Wireless Drug-Delivery System
        • Cordis to Develop Cardiac and Vascular Institute
        • Nanogen Receives Clearance for CHF Test
        • Crestor Reverses Heart Disease
        • Biomet for Sale?
        • Orthopedic Companies Promote Knee Implants for Women
        • Pioneer Surgical, Encelle to Work on Spinal Fusions
        • FDA Approves St. Jude Closure Device
        • Protege by ev3 Receives FDA Approval

Related Tags: , ,

Nanotech/MEMS in medicine (nanomedicine) companies

This is preliminary(!) list of the companies involved in nanotech and/or MEMS with at least a minimum level of activity in applying the technologies to medical applications. This list was updated from a previous report by MMD, but still may included a number of companies (not yet edited out) who ultimately were unable to sustain the rampant, rabid optimism needed to drive investment in support of R&D in this area. We also will likely have a moderate to significant number of additional companies profiled.

Advanced Photonic Systems GmbH

Amersham Biosciences Corp

Anson Nano-Biotechnology Company Ltd

Aphios Corp

Aquamarijn MicroFiltration BV

Avidimer Therapeutics

Biocristal Ltd

Biodelivery Sciences International

Bio-Gate Bioinnovative Materials GmbH

Bionova Inc

Biophan Technologies

Biospectrum

C Sixty

Capsulation Nanoscience AG

CardioMEMS Inc

Digital BioTechnology Co Lts

DIOLAS Diodenlaser GmbH

Fairfield Sensors Ltd

Flamel Technologies SA

Genencor International

HealPlus International Inc

IGI Inc

ImaRx Therapeutics Inc

iMEDD Inc

Improvita Health Products Inc

Insert Therapeutics Inc

JenLab GmbH

JR Nanotech plc

Kereos Inc

Kliendieck Nanotechnik

Liplasome Pharma A/S

Magforce Applications GmbH

MagnaMedics GmbH

ManoMedica Inc

Micralyne Inc

Micromet AG

Micronics Inc

MicroTec Geselschafft fur Mikrotechnologie GmbH

MIV Therapeutics Inc

Molecular Profiles

Nanobac Pharmaceuticals Inc

NanoBio Corp

Nanobiotics

Nanobiotix

Nanocarrier Co Ltd

Nanocopoeia Inc

Nanogate Technologies

Nanogen Inc

NanoMed Pharmaceuticals Inc

Nanomix Inc

NanoPharma AG

Nanostream Inc

Nanosyn Inc

Nanotherapeutics Inc

Nanovax Inc

Newco Surgical

NOSE

Novosom AG

Nucryst Pharmaceuticals

Nutralease Ltd

Petnet Pharmaceuticals Inc

Pharmosol GmbH

Precision Optics Corp

Psvidia Ltd

Silex Microsystems AB

Skyepharma plc

Solubest Ltd

Spherics Inc

Spire Corp

Spinelix

Starpharma Pooled Development Ltd

Tecan Group Ltd

The report is about a week away, depending on how much additional content we feel meets the “absolutely-have-to-include-this” test.

Related Tags: , , , ,

Diabetes markets (Type I & II)

The market for products worldwide in the management of diabetes is the subject of an analysis done by MMD at the end of 2005. While a plethora of studies are available on markets for diabetes-related products, our analysis succeeds uniquely by looking at both established and developing technologies with a more critical eye and doing so in a global analysis.

Worldwide Diabetes Market 2004

Medications

$15,000 million
Diagnostic devices$8,000 million
Insulin therapy devices$275 million
Insulin pumps$1,000 million
TOTAL$24.3 billion

This $24 billion global market — big enough as it stands — represents only the tip of the potential market iceberg, for several important reasons.For the majority of Type 2 diabetes, the adult onset segment, is an undiagnosed, untreated population

  1. A huge pent-up demand exists for improved treatment due to the need for frequent testing (finger pricks) and insulin administrations (pen/syringe)
  2. A huge payer demand exists for effective treatment (read high patient compliance) that reduces the incidence of costly complications
  3. Advancements in diagnosis OR treatment that lead to (pick one) improved quality of life or reduced rate of complication leading to even a modest increase in the penetration of the Type 2 undiagnosed will be a huge boon to the market

So, the technologies being pursued with aggressive energy include:

  • minimally invasive glucose monitors (optical coherence tomography, ultrasonic, measurement, infrared, etc.)
  • closed loop pump/monitor systems (“artificial pancreas”)
  • stem cells (“cure”)

It is very diffiicult to discern between those analyses of the diabetes market that are largely driven by spreadsheet formulas and those that both grind out the hard numbers and apply real insight to determine the defensible timing and impact of technology developments.

Our intention and our belief is that our hard work has produced the latter.

Our VC tracking URLs

These are some of the VC and other sites we track to keep an eye on new investments and new technologies in order to identify formation of new medtech companies.


http://www.atvcapital.com/portfolioGroup.php?id=9

http://www.aperturevp.com/portfolio.htm

http://www.arcapita.com/corporate/current/current-healthcare.html

http://www.canaan.com/portfolio_life.html

http://www.carecapital.com/companies.asp
http://www.dpbioventures.com/

http://www.domainvc.com/Portfolio.asp?Filter=A
http://www.frazierhealthcare.com/portfolio/index.asp
http://www.goldenpineventures.com/portfolio.htm
http://www.herculestech.com/portfolio/portfolio.asp?CompanyID=3225&IndustryID=15

http://www.denovovc.com/portfolio/index.html
http://www.wispartners.com/

http://www.kpcb.com/portfolio/portfolio.php?lifescience

http://www.lifescienceangels.com/content.php?cid=1013
http://www.magicvc.com/portfolio/index.html

http://www.masonwells.com/Portfolio.htm

http://www.massmedic.com/members_primary.htm
http://www.nea.com/PortfolioCompanies/Healthcare/Devices/index.cfm?&SA=1

http://www.nlvpartners.com/portfolio.html#medical
http://silk.nih.gov/public/cbz2zoz.@www.sbirsttr.fy2006.txt
http://www.northbayangels.com/pages/DealsDone.jsp

http://www.onset.com/portfolio/index.html

https://www.pequotventures.com/portfolio/healthcare.html

http://www.pitango.com/portfolio.asp

http://www.polarisventures.com/Portfolio/ViewBySector.asp#

http://www.pwcmoneytree.com/moneytree/nav.jsp?page=industry
http://www.prismventure.com/portfolio/lifescience.asp
http://www.radiusventures.com/healthcare_industry.asp
http://www.tvmvc.com/site/lsportfolio.php
http://www.threearchpartners.com/html/portfolio.html
http://www.tmvp.com/Portfolio.html
http://www.tricardia.com/
http://www.usvp.com/home.html

http://www.devicelink.com/links/venture.html
http://www.versantventures.com/portfolio.html
http://www.wfdventures.com/index.html

Novel technologies in diabetes management

A glimpse of newer technologies in diabetes management (from http://mediligence.com/rpt-d500.htm).

  • Pancreas transplants
  • Islet cell transplants
  • Stem cell developments
  • Antibody treatment
  • Vaccines
  • Genetic approaches (genetic testing, SiRNA)
  • Novel drugs (DDP-IV Inhibitors, NN-14, Rimonabant)
  • Continuous glucose monitoring (electroenzymatic sensor, optical sensor, carbon nanotube sensor)